NEW YORK, Sept. 13, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/cytrx-corporation.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) and that the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/cytrx-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Washington Post Publisher Will Lewis Steps Down After Layoffs
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



